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A B S T R A C TObjectives: To present a step-by-step example of the examination of
heterogeneity within clinical trial data by using a growth mixture
modeling (GMM) approach. Methods: Secondary data from a long-
itudinal double-blind clinical drug study were used. Patients received
enalapril or placebo and were followed for 2 years during the drug
component, followed by a 3-year postdrug component. Primary vari-
ables of interest were creatinine levels during the drug component
and number of hospitalizations in the postdrug component. Latent
growth modeling (LGM) methods were used to examine the treatment
response variability in the data. GMM methods were applied where
substantial variability was found to identify latent (unobserved)
subsets of differential responders, using treatment groups as known
classes. Post hoc analyses were applied to characterize emergent
subgroups. Results: LGM methods demonstrated a large variability in
creatinine levels. GMM methods identified two subsets of patients for
each treatment group. Placebo class 2 (7.0% of the total sample) andsee front matter Copyright & 2013, International S
r Inc.
.1016/j.jval.2012.08.2215
i.org.
ondence to: Donald E. Stull, RTI Health Solutions,
er M20 2LS, UK.enalapril class 2 (8.5%) include individuals whose creatinine levels
start at 1.114 mg/dl and 1.108 mg/dl, respectively, and show worsen-
ing (slopes: 0.023 and 0.017, respectively). Placebo class 1 (43.1%) and
enalapril class 1 (41.4%) individuals start with lower creatinine levels
(1.082 and 1.083 mg/dl, respectively) and show very minimal change
(0.008 and 0.003, respectively). Post hoc analyses revealed significant
differences between placebo/enalapril class 1 and placebo/enalapril
class 2 in terms of New York Heart Association functional ability,
depression, functional impairment, creatinine levels, mortality, and
hospitalizations. Conclusions: GMM methods can identify subsets of
differential responders in clinical trial data. This can result in a more
accurate understanding of treatment effects.
Keywords: differential responders, heart failure, heterogeneity,
mixture model.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Variability in response to treatment is a common finding in
clinical trials, and the study of this has received particular
attention in recent years [1–4]. Patients assigned to treatment
arms come from different backgrounds with different genetic
makeups, life situations, experiences, and stressors. In designing
clinical trials, randomization is used to ensure comparable
groups prior to treatment, reducing the chances that differences
in treatment response are the result of preexisting differences
between treatment groups. Despite these efforts, differential
treatment response can still exist; that is, not all patients in
treatment groups respond in the same way or to the same extent.
This can disguise true treatment effects and potentially mask the
value of products for particular patients by increasing the mean
response where there is a class of hyperresponders or, conver-
sely, decreasing the mean response where there is a class of
hypo- or nonresponders [5]. That is, some patients in active
treatment groups may show no response, or deterioration, andwhen their results are analyzed together with the results of
responsive patients, the overall treatment effect is dampened.
In addition, some patients in placebo groups may show a
‘‘treatment response’’ when such response is not expected or
warranted. Understanding which particular patients are more, or
less, likely to benefit from treatment is important to ensure that
medicine is administered optimally. That is, identifying patients
for whom treatment is effective can aid the development of
personalized medicine.
An indicator that differential response, or heterogeneity, is
present within clinical trial data is the presence of variability
in scores for end points during, or at the end of, a study [6].
Identifying these differential responders obviously has advan-
tages for understanding treatment effect. Such detailed informa-
tion may provide clues that can be used to move us closer to
personalized medicine. These insights can aid in designing
clinical trials that are more appropriately powered, include the
most relevant patients, help minimize the exposure to potentially
toxic treatments of those patients who are likely to be the leastociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 6 4 – 1 7 6 165responsive, and reduce the cost and burden of administering
treatment to such patients.
Of course, some variability in clinical trials is hypothesized
and expected, such as differences between treatment and pla-
cebo groups, across doses, or between comparator drugs. Thus,
multigroup analyses are typically performed to compare the
magnitude of responses between explicitly defined sub-
groups (e.g., treatment and placebo). Latent growth modeling
(LGM) method, a structural equation modeling (SEM) approach,
represents a type of analytic method used to compare predefined
subgroup responses to an intervention [7–9]. LGM methods have
an advantage over methods such as analysis of variance (ANOVA)
or multiple regression in that they can use information from all
assessment points in a single model, control for time-invariant
and time-varying covariates, explicitly model measurement
error, and can include multiple outcome variables simulta-
neously, including (but not limited to) clinical, clinician-reported,
and patient-reported outcomes.
We can define as follows a straight linear LGM method
involving two latent constructs (intercept and slope) in which a
continuous variable, y, is measured across four time points [10]:
yi¼LyZþei ð1Þ
where yi is a p  1 vector of repeated measures containing scores
for individual i (1, 2,y, n) at t (t ¼ 1, 2,y, 4) occasions, Z is defined
as an m  1 vector that contains the intercept and linear growth
factors, and Ly is a p  m design matrix (in the present study, a
4  2 matrix, for four occasions and one intercept and one slope
factor). ei is a p  1 vector (in the present case, a 4  1) of time-
specific residuals for each individual i.
A key assumption of LGM methods is that the growth trajec-
tories (slopes of change) for all individuals can be represented with
a single, common slope parameter [11]. That is, all individuals
show similar changes over time on a given measurement. How-
ever, as discussed above, this assumption may be untenable in
some circumstances for any number of reasons (e.g., different
genotypes, differences in health care use outside the trial protocol,
differences in concomitant medication use, and differences in
family or social support). Differences between individuals can
result in qualitatively and quantitatively different slopes of change
over time [4,5].
When analytic methods using predefined groups account for
only part of the variability in response to treatment (i.e., indivi-
duals within treatment groups continue to exhibit different
change patterns), the analyst may suspect that there are sub-
groups of differential responders within the trial and must
consider other techniques. Some of the heterogeneity in treat-
ment response may be attributable to unobserved but potentially
identifiable factors, such as genetics. Some may be the result of
observed variables that are included as covariates in analyses
(e.g., age, gender, dose, and comorbidities). Still other compo-
nents of the variability may involve data that are collected as part
of the trial but are not explicitly included as covariates in
analyses, including baseline levels and changes in variables.
Finally, treatment response variability could involve contextual
variables outside the study (e.g., different standards of care
across countries in a multicountry trial). In the latter two
examples, the cause of heterogeneity in response must be
inferred from the data.
While various approaches can be used to uncover subgroups
of differentially responsive patients, they may introduce
problems with multiple comparisons or require substantial
amounts of time to conduct the many different subgroup
analyses. For example, in the absence of a predefined criterion
for a nonresponder, responder, or partial responder, using a
traditional approach an analyst must make multiple compari-
sons trying different cutoff values in a variable of interest,violating assumptions of independence. In such circumstances,
the search for differential responders may require dozens or
hundreds of data slices to find those particular patients, model
their slope parameters, and determine their characteristics.
Obviously, this is not an efficient, nor a scientifically rigorous
approach.
Numerous methods, historically, have been available to eval-
uate heterogeneity in data, including discriminant analysis,
multigroup common factor analysis, latent class analysis, and
latent profile analysis. Only the latter three evaluate the data in
terms of a latent (i.e., unobserved) construct accounting for class
assignment [12]. More recently, methods based on SEM have been
developed and used to evaluate the existence of latent classes
within heterogeneous data. Mixture models—factor mixture
models and growth mixture models—are a combination of
common factor and latent class analysis and can allow analysts
to explore patterns of means, variances, and covariances in the
existing data to uncover groups of differential responders [11–13].
Latent variable mixture modeling relaxes the assumption of
LGM that all respondents are drawn from the same population
and thus have a common underlying slope of change. Growth
mixture modeling (GMM) captures the heterogeneity in slopes of
change within the population by modeling distinct subpopula-
tions through incorporating a latent categorical variable [10,12].
Suppose we begin with a growth model and hypothesize that
three distinct growth curves (k ¼ 3 classes) account for the
heterogeneity of patient response to treatment, then Equation 1
is extended very simply:
yik¼nkþLkZikþeik ð2Þ
where k ¼ 1, 2, 3 classes and i ¼ 1, 2,yn cases. An additional
term, nk, is added to represent the intercepts of the continuous
observed variables y for each class, k. In a latent growth curve
model, the y-intercept vector, n, is set to zero and the latent
means are estimated. By including the latent trajectory classes
(k ¼ 1, 2, 3), it allows for heterogeneity of slopes of change
(i.e., treatment response) within the larger population of patients.
These methods can be used with cross-sectional (factor
mixture models) or longitudinal data (growth mixture models)
to explore unobserved subclass homogeneity within observed
population heterogeneity. That is, these analytic methods
can uncover a subset(s) of patients who exhibit within-class
homogeneity yet are themselves different from the larger class
of patients from which they are drawn. Such subsets can be
examined post hoc to see what variables may account for their
class membership, thus differentiating them from the remaining
patients. Several articles that cover this topic have been pub-
lished, such as Muthe´n and Asparouhov [14], who outline
examples of the GMM framework and how this has been applied
to longitudinal studies. Muthe´n et al. [4] outlined the application
of GMM approaches to a small-scale clinical trial of depression
medication and demonstrated successful identification of sub-
sets of differential responders within different treatment arms.
Identification of groups of differential responders within treat-
ment arms is a big step toward furthering the development and
refinement of personalized medicine and should ideally become
a standard approach when analyzing clinical trial data. The
present article builds on previous work by presenting a step-by-
step guide to examining and modeling heterogeneity within
longitudinal large-scale clinical trial data. Moreover, the article
demonstrates how to identify the specific variables belonging to
different subsets of differential responders that may account for
their class membership, through post hoc comparisons between
latent classes. While the goal is to provide a step-by-step example
of conducting these analyses using longitudinal data, along with
some of the potential problems and unresolved issues to be
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in SEM.
The focus of the clinical trial used was to compare the effects
of an angiotensin-converting enzyme inhibitor with placebo to
reduce blood pressure and thus reduce the risk of hospitalization
and death among patients diagnosed with heart failure. The
effect of treatment on the original groups was evaluated in terms
of change in a clinical marker of kidney function (creatinine),
identifying variability in intercepts and slopes of change. We
explored the existence of latent classes of differential respon-
ders, noted any differences in outcomes between latent classes,
and then defined the characteristics of those subsets by
using baseline characteristics and later experiences, such as
hospitalizations.Methods
Study Data
Secondary data from a longitudinal double-blind clinical drug
study, the Studies of Left Ventricular Dysfunction (SOLVD),
were used for these analyses. Details on methodology, including
measures, are available elsewhere [15–19]. The SOLVD involved
83 hospitals affiliated with 23 centers in the United States,
Canada, and Belgium. The main focus was to compare the
effects of an angiotensin-converting enzyme inhibitor—enalapril,
a vasodilator—with placebo on mortality and hospitalization
[15,16]. Although the proximal effect of enalapril is reduction of
blood pressure through vasodilation, thus reducing the load on the
heart, reduction of blood pressure per se will not necessarily be
directly associated with hospitalizations. Thus, for the present
analyses, a more proximal relationship with hospitalizations is
level of creatinine indicating that kidney function is impaired as a
result of the patient’s heart failure.
Sample
Patients were eligible for the SOLVD if they had a left ventricular
ejection fraction of 35% or less, were 21 to 80 years of age, and did
not have severe valvular heart disease, incapacitating/unstable
angina pectoris, myocardial infarction within the previous
month, other life-threatening illness, or a serum creatinine level
of 2.5 mg/dl or more [17]. Enrolled patients (N ¼ 6797) were
followed for 2 years during the drug component and additionally
followed, when possible, for a further 3 years beyond the drug
component to monitor mortality and heart failure–related hospi-
talizations. Patient-reported health-related quality-of-life mea-
sures were collected on 5210 of these patients; these data from
the first four visits (2-year drug study) were used in the present
analyses.
Measures
Primary analyses
Three variables were used to conduct the primary analyses.
Longitudinal data for one variable, creatinine, were used to
generate intercepts and slopes for each participant. Creatinine
is a byproduct of muscle metabolism, and blood serum levels are
used to assess kidney function; ‘‘normal’’ creatinine levels gen-
erally range from 0.6 to 1.2 mg/dl, and an increase is indicative of
reduced kidney function [19]. Kidney function is often lowered in
patients with heart failure, in part because of reduced circulatory
flow. The remaining two variables used in the models were
1) treatment group assignment (enalapril vs. placebo), which
was used to group patients in a multigroup comparison, and 2)
number of hospitalizations in the 3-year postdrug component of
the study.Post hoc analyses
Several other background measures were analyzed to provide
descriptive information about the sample and to facilitate post
hoc examination of the specific characteristics belonging to each
latent class identified through GMM methods. These measures
include age, gender, race/ethnicity, baseline ejection fraction,
New York Heart Association (NYHA) functional class, activities
of daily living (ADLs), instrumental ADLs (IADLs), depression,
and death.
Patient age was measured in years. Race/ethnicity assessed
whether patients were white, black, or Hispanic. Left ventricular
ejection fraction was assessed at baseline and indicates the
proportion of blood being pumped out of the left ventricle of the
heart (the main pumping chamber) with each contraction. The
NYHA functional status classification is a practitioner-assessed,
disease-specific functional status measure that ranges from func-
tional class I (‘‘No symptoms and no limitation in ordinary
physical activity’’) to functional class IV (‘‘Severe limitations.
Experiences symptoms even while at rest’’) [20]. ADLs and IADLs
were assessed by using a 12-item measure with responses on a
four-point scale ranging from 1 (‘‘usually did with no difficulty’’) to
4 (‘‘usually did not do because of health’’) [21]. Thus, higher scores
reflect greater ADL and IADL impairment. Depression was mea-
sured by using the Profile of Mood States , which asks respondents
to indicate how they feel today (e.g., ‘‘tense,’’ ‘‘sad,’’ and ‘‘blue’’) on
a five-point scale (0 ¼ ‘‘not at all’’ to 5 ¼ ‘‘extremely’’) [22]. Higher
scores represent greater depression. Finally, data were collected on
whether the patient died during the 5 years of the SOLVD (2 years
of the drug component and 3 years of follow-up).
Statistical Analysis
Two types of longitudinal analyses were performed on the basis
of data from the first four visits (2-year drug component) of the
trial: LGM and GMM. Each of these types of analyses is described
below.
When samples are large, as in the present study, the data
can be split randomly, and LGM methods and GMM methods can
be used in one random subsample and replicated in a second
random subsample [7]. This replication can yield additional confi-
dence that the findings are not the result of chance. The purpose
of the present article was to present an example of how to
conduct these analyses and interpret the results by using clinical
trial data, rather than to provide scientific evidence for the effect
of enalapril. As such, the clinical results of the models are of less
importance; therefore, the random subsample replication was
not performed to simplify the presentation. Analysts, however,
are encouraged to use this method when the results of the
analyses are the primary interest.
The following sections present a step-by-step guide to using
LGM methods and GMM methods by using clinical trial data.
Step 1—Descriptive statistics
Prior to conducting either type of analysis, it is critical to
examine the distributions of all the variables to be included.
LGM methods and GMM methods are sensitive to deviations in
skewness and kurtosis [7]. Such departures from normality
may require transformation of the variables or the use of
robust estimation of standard errors, but note that the latter
approach requires larger samples. Consequently, the distribu-
tions of creatinine values at each visit and the number of
hospitalizations were examined for skewness and kurtosis to
ensure that these variables did not exhibit departures from
normality.
In addition, visual inspection of mean changes in variables
being used for growth models can give clues to departures
from linearity in the slope trajectories. These can inform the
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methods (e.g., linear vs. quadratic). Therefore, an overview of
descriptive statistics is presented for the trial with an examina-
tion of distribution and normality.Step 2—LGM methods
LGM analyses were conducted in Mplus version 6.1 [23] by using
four assessments of creatinine in the 2-year drug portion of the
SOLVD to calculate two latent, or unobserved, variables: one for
the intercept (variable for the first time point of the curve) and
one for the slopes of change (variable for changes in the scores
over time) for each individual in the study. Note that the intercept
variable is not equivalent to the value of the initial observation
for a respondent but rather the value of the growth curve at the
first assessment point. Intra- and interindividual changes are
assessed by using all available data points. The consequence is
more precise parameter estimates while using data from all
available time points [7].
Referring to Equation 1, for each individual patient (i) we have
creatinine (y) measured at four time points, an intercept and
slope (Z) generated for each patient, the design matrix (L) of four
occasions and two latent variables (intercept and slope), and a
time-specific residual (e) for each patient:
yi¼LyZþei
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The intercepts and slopes were used to predict the number of
heart failure–related hospitalizations in the 3 years following
the drug component. It was anticipated that increases in
creatinine (poorer kidney function) would predict higher num-
bers of heart failure–related hospitalizations. A multigroup
analysis was conducted in which slopes of change in creatinine
were analyzed by treatment group, allowing for comparisons
of the individual effects of treatment group on intercepts,
slopes, and numbers of hospitalizations. Moreover, separate
slopes of change were generated for each treatment group,
allowing for empirical and visual inspection of the slopes for
each group.
Several fit statistics were examined to assess how well a
linear and quadratic slope fit the data. The fit indices detect
differences in describing the data between estimated covar-
iances under the model and estimated covariances under
alternative models. The comparative fit index measures the
improvement in fit from using the hypothesized model over
using a model with independence (i.e., no correlations)
assumed among the variables. The root mean square error of
approximation measures model misspecification in compari-
son to the sample covariances while adjusting for model size
and sample size. The standardized root mean residual mea-
sures the average squared difference between sample correla-
tions and estimated correlations under the model. Although
some disagreement exists in the literature about minimal
acceptable values for fit statistics, the present study uses the
following values to assess the goodness of fit of the model to
the data: comparative fit index 0.90 or more [24,25], root mean
square error of approximation 0.08 or less [26], and standar-
dized root mean residual 0.1 or less [25].
Individual variability around the mean intercept and mean
slope of creatinine levels was examined to assess whether it was
reasonable to relax the assumption of LGM that all respondents
have a common slope.Step 3—GMM methods
Where LGM analyses revealed considerable variability in inter-
cepts and slopes, GMM analyses were conducted. The purpose of
these was to establish whether there were subsets of patients
(latent classes) within each treatment group that had common
intercepts and slopes but whose intercepts and slopes were
different from other subsets of patients. That is, GMM analyses
were conducted to identify subsets of patients with differential
response to 1) active treatment and 2) placebo in terms of change
in creatinine levels. The overall model—that is, the part of the
model that is in common for all latent classes—was built to
generate intercepts and slopes of change in creatinine for each
individual and relate those to the number of hospitalizations in
the subsequent 3 years (postdrug component). In addition, the
latent class probabilities were assumed to be affected by treat-
ment (known class) and allowed to vary across the known
treatment groups in the sample. Thus, different sizes of latent
classes are possible within each treatment group.
GMM analyses were conducted by using Mplus version 6.1 [23]
to assign subjects to their most likely latent class and to obtain
estimates of the model parameters for each class. That is, for
each class extraction (k, k þ 1, k þ 2, etc.), subjects are assigned to
a latent class probabilistically and an assessment can be made
of the accuracy of class assignment for each class extraction.
Initially, latent classes are extracted and different numbers
of classes extracted are assessed. This involves several decision
points based on empirical and visual examinations. Next,
once the optimal number of classes is extracted (supported
by empirical and visual evidence), latent class assignment is
merged with the original data and post hoc comparisons can
be conducted to explore differences between the latent classes
(e.g., in what ways are treatment responders different from
treatment nonresponders?).
Two primary types of GMM analyses can be conducted in the
context of clinical trials: known groups and latent classes only. In
the first instance, ‘‘known groups’’ refers to predefined groups, for
example, treatment groups. Latent classes are examined within
each known group. That is, if treatment and placebo groups are
involved, then one can examine the presence and size of latent
classes of differential responders within each treatment group.
Post hoc analyses involve comparing characteristics of the latent
classes within each treatment arm. In the second instance
(i.e., latent classes only), the presence and size of latent classes
is examined in the entire data set, irrespective of treatment
group. Post hoc analyses involve examining whether treatment
groups are differentially represented in the latent classes, as well
as a comparison of the characteristics of each of the latent
classes.
In the present study, the known-groups approach was used.
A preliminary step involved extracting two latent classes (k) from
each treatment group on the basis of each latent class having
different intercepts and slopes. To validate the findings, a second
analysis was performed on the two latent classes per treatment
group with different random start values to reduce the chance of
a local solution, to determine whether the same number of
classes would be extracted and whether the class assignment
was consistent. Following this, analyses were performed with
k þ 1 classes (i.e., three latent classes) to evaluate whether
extracting k or k þ 1 classes yielded the best model fit. That is,
whether two latent classes or three latent classes per treatment
group most accurately described the data. Again, a follow-on
analysis using different random start values was conducted to
validate the findings. If the analysis with k þ 1 classes ran
successfully and results were potentially informative (e.g., class
sizes were reasonable and differences between classes were
sufficiently defined), these steps were repeated with k þ 2 classes
Table 1 – Sample background characteristics (N ¼ 5210).
Age (y), mean  SD 59.3  10.0
Baseline ejection fraction, mean  SD 26.5  6.5
Number of hospitalizations, mean  SD 1.6  1.8
Creatinine, mean  SD
Visit 1 1.20 0.29
Visit 2 1.23 0.36
Visit 3 1.23 0.36
Visit 4 1.24 0.37
Creatinine (square root), mean  SD
Visit 1 1.09  0.13
Visit 2 1.10  0.16
Visit 3 1.10  0.15
Visit 4 1.10  0.15
Gender, n (%)
Female 799 (15.3)
Male 4411 (84.7)
Race/ethnicity, n (%)
White 4368 (85.1)
Black 641 (12.5)
Hispanic 126 (2.5)
NYHA functional class, n (%)
I 2002 (38.5)
II 2334 (44.9)
III 815 (15.7)
IV 49 (0.9)
Number of hospitalizations, n (%)
0 1747 (33.5)
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identified.
To determine model fit, several decision points based on
empirical and visual examinations were used. These included
the Bayesian information criteria (BIC), sample size–adjusted BIC
(SABIC), entropy, class assignment probabilities, the size of the
smallest latent class extracted, and visual inspection of the latent
class trajectories.
The BIC takes into account sample size and is not standar-
dized:
BIC¼2log Lþp lnðnÞ
where an adjustment is made to the 2 log-likelihood (a badness-
of-fit indicator) based on p, the number of parameters being
estimated in the model, and n, the sample size.
The SABIC takes sample size into account but in a more
appropriate way by replacing the sample size, n, in the BIC with
an adjusted sample size:
SABIC¼2ln Lþp ln nþ2ð Þ=24 
where an adjustment is made to the 2 log-likelihood based on p,
the number of parameters in the model, and n þ 2/24, the sample
size adjustment. While the BIC and the SABIC allow comparisons
of models regardless of the parameterization or the number of
latent classes examined, they do not provide a significance test
to assess the fit of competing models. Instead, deciding on a
preferable model involves comparing relative sizes of these
information criteria. In particular, the BIC and SABIC are scaled
so that smaller values indicate a better-fitting model and are
preferred when choosing between models that differ in the
number of latent classes [27].
Another useful statistic is entropy. Entropy is a summary
statistic that gives an indication of the accuracy of latent class
assignment (posterior probabilities) for each respondent [27,28].
Although there is no conventional level for the threshold value
for entropy, values closer to 1 indicate greater accuracy of latent
class assignment [29]. Inspection of the diagonal and off-diagonal
values in the k  k matrix of posterior probabilities gives an
indication of the correctness of assignment of individuals to each
latent class. Class assignment probabilities were evaluated to
assess class homogeneity (i.e., to see whether the posterior
probabilities on the diagonal are close to 1). In other words, the
likelihood of correctly assigning individuals to a latent class
indicates how homogeneous each class is: The closer to unity,
the more homogeneous the class. The size of latent classes was
considered because very small classes may represent chance
findings and thus give a false indication of the number of latent
classes within the heterogeneous data.
Finally, visual inspection of the latent class trajectories pro-
vided an insight into the reasonableness of the numbers of latent
classes to be considered. This visual inspection allows examina-
tion of the conceptual fit of models, as final class solutions
should be theoretically interpretable and not merely reflect
statistical fit optimization, which could result from a partial
solution as a consequence of local identification. In case a model
did not converge (i.e., the model was not able to run) for a
specified number of latent classes, the remaining models were
compared.1 1329 (25.5)
2 823 (15.8)
3 504 (9.7)
4 282 (5.4)
5 185 (3.6)
6þ 340 (6.5)
NYHA, New York Heart Association.Step 4—Post hoc analyses
Once the optimal number of classes was extracted that best
describe the data (i.e., subjects were assigned to the most likely
latent class), latent class assignment for each patient was merged
with the original trial data and post hoc comparisons were
conducted to explore differences between the latent classes(e.g., how are treatment responders and treatment nonrespon-
ders different in terms of demographic characteristics?).
Post hoc analyses were performed by using Stata version 12.1
[30]. The variables used in post hoc analyses were the following:
age, gender, race/ethnicity, baseline ejection fraction, NYHA
functional class, ADLs, IADLs, depression, and death.
Cross-tabulations with chi-square tests of association and
one-way ANOVAs with Bonferroni were used to compare catego-
rical characteristics and mean differences and proportionality in
scores on external covariates between classes. This approach not
only enhances the validation of class solutions but also provides
important descriptive detail necessary to characterize each latent
class.Results
Within this section, results are presented following the steps
described above. LGM methods were used to examine changes
by each treatment arm and the variability around the mean slopes
for each treatment arm. The amount and type of variability (e.g.,
differences in intercepts, differences in slopes, or both) in the LGM
analyses were used to decide whether to conduct GMM analyses.
This was done by using both empirical and visual information, as
described above. This information is presented in tables and
figures with corresponding explanations of decisions in the text.
Table 2 – Latent growth model: fit statistics and results.
Fit statistics
CFI 0.999
RMSEA 0.017
90% CI of RMSEA 0.002–0.028
SRMR 0.020
Results
Placebo Enalapril
Creatinine
Mean intercept  SD 1.086  0.106 1.087  0.105
Mean slope  SD 0.011  0.017 0.006  0.15
Number of hospitalizations
Mean  SD 1.6  1.7 1.7  1.8
CFI, comparative fit index; RMSEA, root mean square error of
approximation; SRMR, standardized root mean square residual.
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Patients’ (N ¼ 5210) basic background characteristics at baseline
are shown in Table 1. Patients’ mean age was 59.3  10 years,
and the majority were men (84.7%). Baseline ejection fraction
(26.5%  6.5%) was quite low (normal range is 55%–70%; a value
under 40% may indicate heart failure [31]; the inclusion criteria
for the SOLVD was an ejection fraction ofr35%), yet the NYHA
functional class indicated that the vast majority were functional
class I (‘‘No symptoms and no limitation in ordinary physical
activity’’) or II (‘‘Mild symptoms [mild shortness of breath and/or
angina] and slight limitation during ordinary activity’’).
Not surprisingly for a count variable, the number of heart
failure–related hospitalizations postdrug study was slightly
skewed (1.1) and kurtotic (3.3). In addition, the creatinine variable
was highly skewed and kurtotic. As mentioned earlier, LGM1.070
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Fig. 1 – Latent Growth Model: Changemethods and GMM methods are sensitive to departures from
normality. As the number of heart failure–related hospitaliza-
tions variable was only slightly skewed, robust estimation of
standard errors was relied upon to deal with this distribution.
The variable for creatinine was nonnormally distributed and
required transforming to minimize problems with the analyses.
Taking the square root of creatinine transformed the distribution
to a more normal one. This transformed variable was used in all
subsequent analyses. The best transformation for this variable
was to take the square root. This transformed variable was used
in all subsequent analyses. The values for both the original count
metric and the square root of this are included in Table 1. Given
that the number of hospitalizations is a count variable with a
large number of zeros, an alternative approach would be to use a
Poisson model, but that is beyond the scope of this article and is
discussed more in the Discussion section.
Step 2—LGM methods
Results of the multisample LGM analyses are presented in Table 2
and Figures 1 to 3. Visual data in Figure 1 show the mean
intercepts and slopes of change in creatinine for placebo and
enalapril in the 2-year drug component of the SOLVD. Model fit
statistics are all good, indicating a close fit of the hypothesized
model with the data: comparative fit index, a measure of the
goodness of fit, is very close to 1.0; root mean square error of
approximation, a measure of the ‘‘badness of fit,’’ is close to 0 and
its 90% confidence interval is narrow; and the standardized root
mean square residual, the discrepancy between the input corre-
lation matrix and the output correlation matrix (decomposed on
the basis of the hypothesized model), is very small.
There appears to be little difference between placebo and
enalapril in terms of both intercepts and slopes of change in
creatinine (intercept: 1.086 mg/dl and 1.087 mg/dl; change: 0.011
and 0.006, respectively). Moreover, the fit statistics indicate that
constraining the model such that placebo and enalapril have the
same slope is acceptable. However, an examination of the2 3
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in creatinine by treatment group.
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Fig. 2 – Latent Growth Model: Individual slopes of change for 100 randomly selected placebo patients.
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of individual slopes around the group mean slope, by SDs more
than twice as large as the mean slope scores. Thus, it is possible
that there are subsets of differential responders within each
treatment group that are influencing the overall mean slopes and
contributing to the very small observed difference between
treatment groups. Indeed, visual examination of individual
slopes for randomly selected patients in the placebo and enala-
pril groups suggests greater variability. Figure 2 shows the
individual trajectories of change for 100 randomly selected
placebo patients and the mean trajectory of change for the
placebo group, represented by the square marker. Figure 3 shows
the individual trajectories of change for 100 randomly selected0.6
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Fig. 3 – Latent Growth Model: Individual slopes of chaenalapril patients and the mean trajectory of change for the
enalapril group, represented by the triangle marker. Each figures
shows great variability around the mean, reflecting the variability
seen in the empirical results (Table 2). This large dispersion
around the mean intercepts and especially the mean slopes
suggests that an examination for latent classes within each
treatment group may provide a more comprehensive under-
standing of treatment effects. That is, relaxing the assumption
of LGM of common growth trajectory and including latent
categorical variable, k, allows the slope vector, Z, to vary by latent
class, reducing ei by further differentiating the residuals within
latent class. Thus, GMM analyses were conducted to analyze
individual change trajectories and the possibility of subsets of2 3
y Visit
nge for 100 randomly selected enalapril patients.
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 6 4 – 1 7 6 171differential responders potentially hidden in the variability
observed through LGM analyses.Step 3—GMM Methods
GMM analyses were conducted with two prespecified known
groups (i.e., treatment and placebo). Within these known groups,
different specified numbers of latent class solutions were exam-
ined to determine which solution had the best fit—that is, the
number of latent classes within each treatment group that most
accurately explained the observed variance. For example, in a
two-latent class solution, the model was designed to identify,
within each treatment group, two classes of patients, each of
which would have its own intercept and slope, but each class’s
intercept and slope would be distinctly different from that of the
other class within the treatment group.
The model fit information for each GMM conducted is pre-
sented in Table 3. The four-latent class model had the smallest
BIC and SABIC values, indicating that this model may have the
best fit for the data. The smallest class, however, within this four-
latent class solution is 0.2% of the total trial sample, suggesting a
questionable latent class. In particular, the smallest class size for
the four-latent class solution included just 10 patients out of
5210, with the next smallest class size composed of 60 patients.
Thus, there could be questionable reliability of parameter esti-
mates for the smallest class in the four-latent class solution
[4,32]. This solution was therefore discounted as a reliable fit with
the data. The best BIC and SABIC for the remaining solutions
came from the three-latent class solution. The entropy values,
however, suggest that assignment of patients to latent classes is
preferable for the two-latent class solution and the one-latent
class solution (essentially the LGM where latent class ¼ known
class of treatment group). Moreover, the size of the smallest class
is more acceptable in the two-latent class solution than in the
three-latent class solution. Furthermore, inspection of the aver-
age latent class probabilities (Table 3) shows that two of the six
latent classes in the three-class solution (i.e., three per treatment
group) have considerably smaller probabilities of assigning
patients to the correct latent class, suggesting that this solution
may not be optimal. Thus, the fit statistics suggest that a two-
latent class solution is the best fit for the data.
Finally, a visual inspection of the observed trajectories of
individuals classified into three classes within each treatment
group (Fig. 4) and two classes within each treatment group (Fig. 5)
suggests that a two-latent class solution is a reasonable model for
the present data. Specifically, the two subsets of slopes have distinct
intercepts and slopes (Fig. 5), whereas in the three-class solution
(Fig. 4), subsets of classes are not as easily discernible visually.
The following sections describe and compare the intercepts
and trajectories of change within the emergent subgroups.Placebo subgroups
The two latent classes emerging within the placebo group indicate
distinct subsets of patients with different intercepts and slopes of
change (Fig. 5 and Table 4). In placebo class 1, an estimated 43.1%
of the total trial sample emerged with a lower intercept value
(1.082 mg/dl) and slope of change (0.008). Placebo class 2, an
estimated 7.0% of the total sample, had a higher intercept value
(1.112 mg/dl) and slope of change (0.023). In general, the normal
range for creatinine is 0.6 to 1.2 mg/dl. Thus, both placebo classes
started within the normal range, but the worsening in placebo
class 2 brings the value close to the top of the normal range. In
addition, the mean number of hospitalizations during the 3-year
postdrug component was significantly lower for placebo class 1
than for placebo class 2 (1.0 vs. 5.1, F ¼ 5524.01; Po 0.001).
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Fig. 4 – Growth Mixture Model: Change in creatinine for a 3-latent class solution per treatment group.
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Fig. 5 – Growth Mixture Model: Change in creatinine for a 2-latent class solution per treatment group.
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Table 4 – Growth mixture model: Intercepts, slopes of change, and number of hospitalizations for each class within a two-
latent class solution.
Placebo Enalapril
Class 1 (43.1%) Class 2 (7.0%) Class 1 (41.4%) Class 2 (8.5%)
Creatinine
Mean intercept  SD 1.082  0.102 1.114  0.121 1.083  0.103 1.108  0.115
Mean slope  SD 0.008  0.015 0.023  0.017 0.003  0.014 0.017  0.020
Number of hospitalizations
Mean  SD 1.0  1.0 5.1  0.9 1.1  1.0 5.0  0.9
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As with placebo, two classes emerged within the enalapril group
with distinct intercepts and slopes of change: enalapril class 1
(an estimated 41.4% of the sample) had a mean intercept of
1.083 mg/dl and a mean slope of 0.003, while enalapril class 2
(an estimated 8.5% of the sample) had an intercept of 1.105 mg/dl
and a slope of 0.017 (Fig. 5 and Table 4). Thus, like placebo,
enalapril class 1 includes individuals whose creatinine levels
start lower and show very minimal change while enalapril class 2
includes individuals whose creatinine levels start higher and
show worsening. In addition, the mean number of hospitaliza-
tions during the 3-year postdrug component was significantly
smaller for enalapril class 1 than for enalapril class 2 (1.1 vs. 5.0,
F ¼ 5663.29; Po 0.001).
Step 4—Post hoc analyses of emergent subgroups
Post hoc comparisons were conducted to uncover potential
reasons for differences in intercepts and slopes of change in
creatinine and in the number of heart failure–related hospitaliza-
tions. These analyses may help characterize the different latent
classes and give an indication of those most in need of treatment
and most likely to respond.
The four latent classes were compared on several background
variables (age, left ventricular ejection fraction, NYHA functional
class, ADL and IADL, depression, and gender), two outcome
variables (number of postdrug study hospitalizations and death),
and the intercept and slope of change in creatinine. Table 5Table 5 – Post hoc analyses: Comparison of characteristics betw
treatment group.
Placebo
Class 1 C
(43.1%)
Age (y), mean  SD 59.2  10.2 60.
Left ventricular ejection fraction (%) 26.4
NYHA functional class (I–IV), mean  SD 1.8  0.7 2.
ADL and IADL impairments, mean  SD 20.8  7.7 23.
Depression, mean  SD 6.5  9.0 8.
Gender, % males 85.1
Number of hospitalizations, mean  SD 1.0  1.0 5.
Patient died during study, % yes 24.0
Creatinine intercept, mean  SD 1.082  0.102 1.11
Creatinine slope of change, mean  SD 0.008  0.01 0.02
ADL, activities of daily living; IADL, instrumental activities of daily livin
* Significant difference between placebo class 1 and placebo class 2 at P
† Significant difference between enalapril class 1 and enalapril class 2 a
z Significant difference between placebo class 1 and enalapril class 1 at
y Significant difference between placebo class 2 and enalapril class 2 atpresents the results of one-way ANOVAs with Bonferroni post
hoc tests of significance.
Almost all comparisons resulted in significant differences
between the two placebo classes and between the two enalapril
classes. In particular, the patients in placebo and enalapril class 1
had better NYHA functional class, had less ADL and IADL
impairments, had lower depression scores, had fewer postdrug
heart failure–related hospitalizations, were much less likely to
die during the SOLVD, had lower intercept values (better creati-
nine levels), and had flatter slopes (less worsening) in creatinine
over the 2 years of the drug.
In addition, there were significant differences between
placebo class 1 and enalapril class 1 and between placebo
class 2 and enalapril class 2. Specifically, class 1 of placebo and
enalapril started at a lower level of creatinine and showed little
change over the 2 years, but placebo class 1 showed a signifi-
cantly greater increase than did enalapril class 1. Patients in
placebo class 1 versus enalapril class 1, however, had signifi-
cantly fewer postdrug heart failure–related hospitalizations and
were less likely to die during the SOLVD.
Class 2 of placebo and enalapril started with higher creati-
nine levels and the slopes increased over the 2 years of the
drug study. Placebo class 2, however, creatinine levels
increased (worsened) significantly more than did those of
enalapril class 2. In addition, placebo class 2 patients were
significantly more likely to die than enalapril class 2 patients
during the SOLVD. No further significant differences were
found for the between-class comparisons (Table 5).een each latent class within a two-class solution per
Enalapril Differences
lass 2 Class 1 Class 2
(7.0%) (41.4%) (8.5%)
1  9.5 59.4  10.2 59.6  10.1 –
26.8 26.5 26.0 –
0  0.8 1.8  0.7 2.0  0.8 , †
4  8.8 21.1  8.1 23.9  8.1 , †
2  10.7 6.4  9.0 7.9  10.1 , †
84.3 84.1 85.4 –
1  0.9 1.1  1.0 5.0  0.9 , †, z
40.2 28.5 35.4 , †, z, y
4  0.121 1.083  0.103 1.108  0.115 , †
3  0.02 0.003  0.01 0.017  0.02 , †, z, y
g; NYHA, New York Heart Association.
r 0.05.
t P r 0.05.
P r 0.05.
Pr 0.05.
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This article presents a step-by-step example of conducting and
interpreting GMM analyses. The goal was to demonstrate, in
some detail, the use of GMM methods to examine the variability
in responses in clinical trial data to see whether there are subsets
of patients who respond differently to treatment. These methods
represent an advance in efficiency and rigor in examining
variability to uncover potential treatment responders and treat-
ment nonresponders in clinical trial data. While only one soft-
ware package (Mplus) was presented for the LGM methods and
GMM methods, other SEM programs can perform these analyses.
We presented Mplus as it is what we are most familiar with and
there is substantial support on the Mplus Web site to help
analysts with issues that arise or to help them get started with
these methods.
Typically, clinical trial data are analyzed by using repeated-
measures ANOVA or mixed-effects regressions. As noted else-
where [7], these methods have shortcomings compared with the
more recent LGM methods. Although LGM methods are advanta-
geous compared with these other methods, they assume that all
respondents have a common trajectory of change. The present
study, however, has demonstrated that this is not true of all
clinical trial data. The observed variability hinted at the presence
of differential responders, which were successfully modeled and
identified through the use of GMMmethods. Thus, when analysts
note variability in baseline scores (e.g., patient-reported out-
comes, clinician-reported outcomes, and laboratory tests) and
changes in these scores across a clinical trial, particularly when
individual trajectories do not follow a common form, GMM
methods can be used to examine this variability for classes of
differential responders. If latent classes are identified with GMM
methods, post hoc analyses can be conducted to identify the
characteristics of each of the classes.
Treatment responders can be compared with treatment non-
responders when such definitions are available a priori. When
such definitions or responder criteria, however, are not available
or established, GMM methods can be used to identify subsets of
respondents who show greater or lesser change. These methods
are more efficient than a series of subgroup analyses that may
involve different cut points of a variable (e.g., different age
groups) or combinations of variables and will not result in
multiplicity because they are conducted as a single analysis.
The GMM method allows the group membership to emerge from
the data and thus it efficiently allows for latent group identifica-
tion that otherwise may not be possible when partitioning the
data in typical subgroup analyses. Moreover, they allow identifi-
cation of individuals who may show a ‘‘hyper’’ response to
treatment, in that a group may emerge who has a very large
improvement, which is much larger than a clinically meaningful
cutoff point. It would be unwise, however, to ignore previous
research that has established information, which may explain
group membership or allow a priori hypotheses. In addition, we
advise consulting with clinicians in the field of research interest
when designing and conducting analyses involving GMM meth-
ods. Their expertise can inform the inclusion of necessary
covariates, advise on anticipated and observed latent class
membership and the potential factors determining such mem-
bership, and confirm findings from post hoc analyses to ensure
that these results support what clinicians expect and see in
practice. Thus, incorporating knowledge from previous research
and clinical experience works toward ensuring that emergent
latent classes are supported and confidence can be had in the
findings.
Several key decision points occur in the process of analyzing
data in this context. First, and perhaps most obvious, is toexamine the data for variability, particularly variability in inter-
cepts and slopes of change in the key variable(s) of interest.
The ability to examine variability in multiple outcome variables
simultaneously is one aspect where LGM methods and GMM
methods are more informative than mixed-effects regressions.
A second decision point is with regard to the degree of
departure from normality in variables included in the analyses.
Because LGM methods and GMM methods are affected by
distributions that are skewed or kurtotic, it is important to
examine the distributions of all variables and make decisions
about how best to transform them. In the present example,
creatinine showed some small skewness and kurtosis. This
variable was transformed to a more normal distribution by
taking the square root and using that transformed variable in
the analyses.
Third, the distribution on the dependent variable, number of
hospitalizations, was a count variable with many 0 values (i.e., no
hospitalizations). An appropriate method for analyzing these
data would be a zero-inflated Poisson model that can be imple-
mented in mixture models in Mplus. We purposely chose not to
use this method because this article is a more didactic presenta-
tion of analyzing heterogeneous data. However, analysts should
consider this approach for dependent variables that are count
variables with large numbers of 0 values.
A fourth decision point involves examining the results of a
series of analyses in which different numbers of classes are
extracted and different random starts are used for each class
extraction. This process is twofold. First, using multiple random
starts helps to ensure that the results of any class extraction are
not the consequence of chance resulting from a local solution.
Second, reviewing the results of extracting different numbers of
latent classes allows comparisons of the relative fit of each model
from multiple statistics (BIC, SABIC, entropy) and visual exam-
ination. It is important to note in this context that nonnormal
data may give the analyst the impression that latent classes can
explain the data patterns rather than there being actual substan-
tively meaningful subgroups [14].
How one decides on the ‘‘correct’’ number of latent classes
that account for heterogeneity in responses remains one of the
most challenging tasks for analysts conducting GMM analyses
[27,33]. There is no one commonly accepted statistical indicator
for deciding on the number of classes in a study population. As
seen in the present article, a number of statistical tests and fit
statistics, in addition to visual inspections, are used to gain an
insight into the likely numbers of latent classes. Which fit
statistic gives the best indication of the ‘‘correct’’ number of
latent classes is still an area of study and debate [27,33]. For the
present purposes, suffice to say that consideration of the multiple
statistics and visual examination, and the logic of the results of
the post hoc analyses, will be needed to gain confidence in the
findings. In the context of clinical trials, confirmation from
clinical experience may help shed light on the veracity of the
latent classes extracted.
Finally, attrition is an issue in many clinical trials, including
the SOLVD. A discussion of handling missing data is beyond the
scope of this article and the reader is referred to many useful
references [34–37]. In the SOLVD, 28% of the patients in this
sample died during the course of the trial, with slightly more
patients in the treatment group compared with the placebo
arm (29.7% vs. 26.3%). Death during the trial, however, was not
associated with treatment group and was only very weakly
associated with creatinine (r ¼ 0.15). Thus, it seems likely that
for our purposes, the data are missing at random. The analyses
were then run two different ways: with listwise deletion and with
full information maximum likelihood (FIML) estimation for miss-
ing data. FIML does not impute values for missing data; rather it
adjusts the means and variance-covariance matrix on the basis
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about the mean and variance of missing portions of a variable,
given the observed portion(s) of other variables. Thus, we ran the
analyses by using listwise deletion and FIML and compared
the parameter estimates of the two analyses. In general, the
parameter estimates (means, variances, covariances, intercepts,
and slopes) were nearly identical. Thus, in this instance, the
overall results and conclusions are the same regardless of using
listwise deletion or FIML. In other studies, however, it is quite
possible that the mechanism of missing does not permit the use
of FIML (e.g., in oncology studies where missing is not a random
event but is related to death and disease progression, which are
also likely to be associated with the treatment itself). Analysts
should examine the data for mechanisms of missing and con-
sider other methods to address these missing data [37–40].
Baseline differences identified in post hoc analyses may
provide clues for patient care about those who will be more or
less responsive to treatment or those who should be monitored
more closely. For example, the creatinine intercepts for class 2 of
both the placebo and enalapril groups are more than one SD
higher (worse) than those of class 1 of the two treatment groups,
indicating a significantly worse baseline creatinine level. Given
the higher levels of baseline creatinine level in placebo class 2
and enalapril class 2 and their continued decline, these indivi-
duals could represent a subgroup that is in greater need of
treatment or monitoring. An examination of the number of
hospitalizations for each of these classes supports this recom-
mendation as well (Table 4), with both placebo class 2 and
enalapril class 2 having significantly higher numbers of heart
failure–related hospitalizations. In addition, they have worse
NYHA functional class, greater depression, and greater functional
impairments. Clinicians may consider alternative or adjunctive
treatments or more frequent visits to monitor the patients’
progress under treatment for patients with these characteristics.
Analysts may want to consider multivariate comparisons of
latent classes. Whereas we have performed univariate post hoc
analyses, multivariate analyses could show the relative impor-
tance of each variable and allow analysts or clinicians to estab-
lish prognostic rules for membership in specific latent classes.
Results of GMM methods can be used for informing designs of
clinical trials. For example, if conducted early in a clinical trial
program, the results of these analyses can be used to modify
inclusion/exclusion criteria and more accurately power trials,
saving substantial resources. That is, patients who are less
responsive can be characterized and those patient characteristics
can be part of the exclusion criteria in protocols for subsequent
trials. This can reduce the variability around mean responses and
potentially give a more accurate view of the efficacy of treatment.
Further, this may require that fewer patients are enrolled into a
trial for the same or better effect size, thus saving substantial
amounts of money on the trial and the overall trial program.
Moreover, this could prevent exposing patients least likely to
respond to a relatively ineffective drug and associated side
effects, and thus could lead to more ethical clinical trials.
Although these methods are exploratory by their design, the
results can be validated by conducting them across multiple trials
to see whether similar numbers of latent classes result and the
characteristics of the classes are similar—as evidenced by Stull
et al. [5]. Alternatively, if a single clinical trial is large enough,
such as the current SOLVD analyses, the random subsamples
without replacement can be drawn and GMM analyses could be
conducted in one random subsample and replicated in a second
random subsample. Either the analyst can compare the estimates
and fit statistics side by side or a more rigorous multisample
analysis can be conducted, allowing for statistical tests of fit
demonstrating that the estimates in the two random subsamples
are, in fact, not statistically different. This would lend confidencethat the results (e.g., the number of latent classes, their relative
sizes, their intercepts and slopes, and correct classification of
individuals to latent classes) were not due to chance. Certainly,
the size of the SOLVD data used here (N ¼ 5210) would easily lend
itself to such an approach. However, given the didactic, rather
than substantive, nature of this article, we opted to use the full
sample to demonstrate the steps and decisions involved in these
analyses.
These methods are extremely flexible and powerful, allowing
analysts to examine large data sets relatively quickly, including
studying multiple outcome variables simultaneously. For exam-
ple, analysts may want to see whether there are differences in
response to treatment for two outcomes, one a patient-reported
outcome and the other a clinical laboratory test, to see whether
there are differences in patient responses, and to see whether
these correspond with physiological tests following an interven-
tion. Likewise, time-invariant and time-varying covariates can be
included in these models to allow for such things as changes in
dose or events such as hospitalization. A note of caution about
performing these analyses is needed, though: these methods
require a solid grounding in SEM. There are many nuances about
model design and interpreting the output for possible indicators
of problems that are recognizable with practice, and so analysts
considering using these methods should be well versed in SEM
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